| Literature DB >> 33377223 |
Asato Otsubo1, Yasuyoshi Miyata1, Tomohiro Matsuo1, Yuta Mukae1, Kensuke Mitsunari1, Kojiro Ohba1, Hideki Sakai1.
Abstract
OBJECTIVE: To assess the relationship between visceral fat accumulation and lower urinary tract symptoms in female patients.Entities:
Keywords: lower urinary tract symptoms; overactive bladder; visceral fat
Year: 2020 PMID: 33377223 PMCID: PMC8048866 DOI: 10.1111/iju.14476
Source DB: PubMed Journal: Int J Urol ISSN: 0919-8172 Impact factor: 3.369
Fig. 1CT images used to measure body fat accumulation. The red area represents visceral fat and the blue area represents subcutaneous fat. (a) The range from diaphragm to pelvic floor: VFV and SFV. (b) Umbilical section: AC, VFA and SFA.
Patient characteristics
| Entire | Non‐OAB | OAB |
| |
|---|---|---|---|---|
| No. patients (%) | 182 (100) | 111 (61.0) | 71 (39.0) | – |
| Age (years) | 57.7 ± 15.3 | 52.7 ± 14.8 | 65.5 ± 12.6 | <0.001 |
| BMI (kg/m2) | 22.4 ± 4.2 | 21.9 ± 3.1 | 23.1 ± 5.3 | 0.071 |
| <18.5 kg/m2 (%) | 32 (17.6) | 18 (16.2) | 14 (19.7) | 0.148 |
| 18.5 to <25 kg/m2 (%) | 115 (63.2) | 76 (68.5) | 39 (54.9) | |
| ≥25 kg/m2 (%) | 35 (19.2) | 17 (15.3) | 18 (25.4) | |
| Comorbidities | ||||
| Hypertension (%) | 46 (25.3) | 17 (15.3) | 29 (40.9) | <0.001 |
| Diabetes mellitus (%) | 12 (6.6) | 4 (3.6) | 8 (11.3) | 0.064 |
| Hyperlipidemia (%) | 24 (13.2) | 9 (8.1) | 15 (21.1) | 0.001 |
| Renal dysfunction (%) | 50 (27.5) | 22 (19.8) | 28 (27.5) | 0.006 |
| OABSS | ||||
| Q1 daytime frequency | 0.3 ± 0.6 | 0.2 ± 0.5 | 0.5 ± 0.7 | <0.001 |
| Q2 nocturia | 1.2 ± 1.0 | 0.7 ± 0.8 | 1.9 ± 0.9 | <0.001 |
| Q3 urgency | 1.2 ± 1.4 | 0.2 ± 0.4 | 2.7 ± 0.9 | <0.001 |
| Q4 urgency incontinence | 0.4 ± 1.0 | 0.1 ± 0.4 | 1.0 ± 1.4 | <0.001 |
| Total OABSS | 3.2 ± 3.1 | 1.3 ± 1.4 | 6.2 ± 2.6 | <0.001 |
| Uroflowmetry | ||||
| Voided volume (mL) | 207.3 ± 109.7 | 232.8 ± 115.7 | 167.4 ± 86.2 | <0.001 |
|
| 18.4 ± 9.6 | 20.3 ± 9.9 | 15.5 ± 8.4 | <0.001 |
| PVR (mL) | 28.8 ± 39.7 | 30.8 ± 44.7 | 25.7 ± 30.4 | 0.401 |
Body fat accumulation
| Entire | Non‐OAB | OAB |
| |
|---|---|---|---|---|
| AC (cm) | 81.6 ± 9.7 | 80.8 ± 7.6 | 82.9 ± 12.2 | 0.145 |
| SFA (cm2) | 150.0 ± 74.8 | 151.6 ± 67.7 | 147.4 ± 85.2 | 0.714 |
| SFV (cm3) | 3701.9 ± 1927.2 | 3718.9 ± 1650.4 | 3675.3 ± 2307.0 | 0.882 |
| VFA (cm2) | 79.2 ± 49.9 | 69.4 ± 39.3 | 94.7 ± 60.2 | <0.001 |
| VFV (cm3) | 2022.6 ± 1371.1 | 1705.6 ± 1009.8 | 2518.2 ± 1688.1 | <0.001 |
| TAV (cm3) | 5724.5 ± 3051.8 | 5424.5 ± 2440.3 | 6193.5 ± 3789.3 | 0.097 |
| VFA/SFA | 0.68 ± 1.39 | 0.48 ± 0.22 | 1.00 ± 2.17 | 0.014 |
| VFV/SFV | 0.61 ± 0.59 | 0.47 ± 0.21 | 0.84 ± 0.87 | <0.001 |
| SFV/TAV | 0.65 ± 0.12 | 0.69 ± 0.09 | 0.59 ± 0.13 | <0.001 |
| VFV/TAV | 0.35 ± 0.12 | 0.31 ± 0.09 | 0.41 ± 0.13 | <0.001 |
Differences of body fat accumulation among the severity of OAB
| Non‐OAB | OAB mild | OAB moderate/severe |
| |
|---|---|---|---|---|
| No. patients | 111 | 35 | 36 | – |
| AC (cm) | 80.8 ± 7.6 | 83.8 ± 8.0 | 82.1 ± 15.3 | 0.260 |
| SFA (cm2) | 151.6 ± 67.7 | 154.5 ± 59.1 | 140.5 ± 105.0 | 0.689 |
| SFV (cm3) | 3718.9 ± 1650.4 | 3868.4 ± 1917.4 | 3487.6 ± 2645.7 | 0.702 |
| VFA (cm2) | 69.4 ± 39.3 | 104.1 ± 49.1 | 85.5 ± 68.8 | <0.001 |
| VFV (cm3) | 1705.6 ± 1009.8 | 2635.2 ± 1311.5 | 2404.5 ± 2000.4 | <0.001 |
| TAV (cm3) | 5424.5 ± 2440.3 | 6503.6 ± 3003.0 | 5892.0 ± 4446.0 | 0.178 |
| VFA/SFA | 0.48 ± 0.22 | 0.70 ± 0.27 | 1.30 ± 3.04 | 0.009 |
| VFV/SFV | 0.47 ± 0.21 | 0.71 ± 0.27 | 0.96 ± 1.19 | <0.001 |
| SFV/TAV | 0.69 ± 0.09 | 0.60 ± 0.09 | 0.59 ± 0.15 | <0.001 |
| VFV/TAV | 0.31 ± 0.09 | 0.40 ± 0.09 | 0.41 ± 0.16 | <0.001 |
P < 0.05 versus non‐OAB.
P < 0.001 versus non‐OAB.
Body fat accumulation and OAB symptom score
|
|
| |
|---|---|---|
| AC (cm) | 0.053 | 0.477 |
| BMI (kg/m2) | 0.082 | 0.273 |
| SFA (cm2) | −0.081 | 0.277 |
| SFV (cm3) | −0.078 | 0.295 |
| VFA (cm2) | 0.125 | 0.092 |
| VFV (cm3) | 0.191 | 0.010 |
| TAV (cm3) | 0.037 | 0.624 |
| VFA/SFA | 0.269 | <0.001 |
| VFV/SFV | 0.330 | <0.001 |
| SFV/TAV | −0.394 | <0.001 |
| VFV/TAV | 0.394 | <0.001 |
Relationship between objective findings and body fat accumulation
| Voided volume |
| PVR | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| AC (cm) | −0.150 | 0.044 | −0.005 | 0.819 | −0.052 | 0.488 |
| BMI (kg/m2) | −0.245 | <0.001 | −0.088 | <0.001 | −0.093 | 0.211 |
| SFA (cm2) | −0.029 | 0.695 | 0.022 | 0.765 | −0.092 | 0.216 |
| SFV (cm3) | −0.051 | 0.493 | 0.016 | 0.826 | −0.060 | 0.422 |
| VFA (cm2) | −0.300 | <0.001 | −0.248 | <0.001 | −0.088 | 0.236 |
| VFV (cm3) | −0.304 | <0.001 | −0.210 | 0.004 | −0.089 | 0.235 |
| TAV (cm3) | −0.169 | 0.023 | −0.084 | 0.259 | −0.078 | 0.298 |
| VFA/SFA | −0.101 | 0.176 | −0.154 | 0.038 | 0.100 | 0.183 |
| VFV/SFV | −0.158 | 0.033 | −0.209 | 0.005 | 0.178 | 0.016 |
| SFV/TAV | 0.291 | <0.001 | 0.289 | <0.001 | 0.040 | 0.588 |
| VFV/TAV | −0.291 | <0.001 | −0.289 | <0.001 | −0.040 | 0.588 |
Univariate and multivariate analysis for OAB
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| Age | 1.07 | 1.09–1.10 | <0.001 | 1.02 | 1.01–1.03 | 0.044 |
| BMI | 1.07 | 0.87–1.01 | 0.072 | – | – | – |
| AC | 1.10 | 0.95–1.01 | 0.144 | – | – | – |
| VFV/TAV | 7.04 | 3.34–12.5 | <0.001 | 3.79 | 1.87–7.80 | <0.001 |
| MetS‐related diseases | 4.25 | 2.26–8.02 | <0.001 | 2.91 | 1.47–5.78 | 0.002 |